SCHEMBL835287

SCHEMBL835287

Cc1ccc2c(c1)c(Sc1ccc(Br)cc1)cc(=O)n2C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 2/20 0.43
TP53 P04637 2/20 0.43
MAPT P10636 5/20 0.43
LMNA P02545 4/20 0.43
SMN1; SMN2 Q16637 4/20 0.43
NPSR1 Q6W5P4 4/20 0.43
HTT P42858 3/20 0.43
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
POLB P06746 2/20 0.43
PRNP P04156 1/20 0.41
KDM4E B2RXH2 3/20 0.41
NQO2 P16083 1/20 0.41
L3MBTL1 Q9Y468 3/20 0.39
NTSR1 P30989 1/20 0.39
ATM Q13315 1/20 0.39
CSF1R P07333 1/20 0.37
ALDH1A1 P00352 2/20 0.36
BRD4 O60885 1/20 0.36
HPGD P15428 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL836066 0.92 RXFP1 (0.48) RXFP1TP53MAPTLMNASMN1; SMN2
SCHEMBL14302623 0.86 LMNA (0.43) RXFP1TP53MAPTLMNASMN1; SMN2
SCHEMBL829660 0.86 MEN1 (0.43) RXFP1TP53MAPTLMNASMN1; SMN2
SCHEMBL836059 0.86 RHEB (0.50) RXFP1TP53MAPTLMNASMN1; SMN2
SCHEMBL835284 0.86 RXFP1 (0.43) RXFP1TP53MAPTLMNASMN1; SMN2
SCHEMBL836042 0.85 HTT (0.49) RXFP1TP53MAPTLMNASMN1; SMN2
SCHEMBL834986 0.85 MAPT (0.56) RXFP1TP53MAPTLMNASMN1; SMN2
SCHEMBL14302622 0.84 LMNA (0.41) RXFP1TP53MAPTLMNASMN1; SMN2
SCHEMBL835001 0.81 RXFP1 (0.44) RXFP1TP53MAPTLMNASMN1; SMN2
SCHEMBL14300144 0.80 RXFP1 (0.58) RXFP1TP53MAPTLMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143276-B2 4-thio substituted quinoline and naphthyridine compounds XTL BIOPHARMACEUTICALS LTD. (IL) 2012-03-27 US disclosed
US-8143276-B2 4-thio substituted quinoline and naphthyridine compounds XTL BIOPHARMACEUTICALS LTD. (IL) 2012-03-27 US disclosed
US-20090054477-A1 4-thio substituted quinoline and naphthyridine compounds PRESIDIO PHARMACEUTICALS, INC. 2009-02-26 US disclosed
US-20090054477-A1 4-thio substituted quinoline and naphthyridine compounds PRESIDIO PHARMACEUTICALS, INC. 2009-02-26 US disclosed
WO-2008024423-A2 4-THIO SUBSTITUTED QUINOLINE AND NAPHTHYRIDINE COMPOUNDS XTL BIOPHARMACEUTICALS LTD. (US) 2008-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054477-A1 4-thio substituted quinoline and naphthyridine compounds GTF3C4, HNF4A, TENT4A RXFP1 4782/4885TP53 335/4885MAPT 2002/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.